Oral Herpes Tied to Double Dementia Risk in Older Adults Oral Herpes Tied to Double Dementia Risk in Older Adults
Herpes simplex virus (HSV) is associated with an increased risk for dementia but cytomegalovirus (CMV) is not, new observational data suggested.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - March 1, 2024 Category: Psychiatry Tags: Neurology & Neurosurgery Source Type: news
Herpes-Dementia Link; How COVID Affects the Brain; FDA to Decide on Duchenne Drug
(MedPage Today) -- A prospective study in Sweden reported a link between herpes simplex virus and dementia. (Journal of Alzheimer's Disease)
Researchers differentiated people with Parkinson's disease from healthy controls with 68% accuracy using... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - February 20, 2024 Category: Neurology Source Type: news
Prone to cold sores? You may have DOUBLE the risk of dementia later in life, study suggests
Researchers from Sweden found that people who have been infected with the herpes simplex virus - which causes cold sores - were twice as likely to develop all forms of dementia. (Source: the Mail online | Health)
Source: the Mail online | Health - February 16, 2024 Category: Consumer Health News Source Type: news
Dartmouth Researchers Offer New Insights into How Antibodies Function Against HSV
Findings from a new study from researchers at Dartmouth’s Geisel School of Medicine and Thayer School of Engineering and published in Cell Reports Medicine, offer new insights into how antibodies function in combating herpes simplex virus (HSV) infections. Their research may lead to possible new treatments for neonatal herpes. (Source: News at Dartmouth Medical School)
Source: News at Dartmouth Medical School - February 12, 2024 Category: Hospital Management Authors: Timothy Dean Tags: News Research herpes simplex virus HSV Iara Backes Matthew Slein Source Type: news
When Should We Consider A Rickettsial Disease?
Discussion
Rickettsioses are “small, obligate intracellular, gram-negative, aerobic coccobacillary α-proeobacteria” from the genuses Rickettsia, Anaplasma, Coxiella, Ehrlichia, and Orientia genuses. Often they cause limited health problems but can cause severe disease and death. They present with a fever and other non-specific signs and symptoms, usually with a rash and lymphadenopathy. Other problems can include:
Cardiac – endocarditis, myocarditis, pericarditis
Gastrointestinal – abdominal pain, acute abdomen, cholecystitis, hepatitis, pancreatitis
Heme/Lymph – hemophagocytosis, lymph...
Source: PediatricEducation.org - December 18, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
How Late Can You Give Routine Newborn Care?
Discussion
Routine newborn screening and treatment is focused on assisting the infant’s transition to extrauterine life, screening for health problems that may or may not be easily identifiable, and preventing acute or chronic health problems. Healthy infants begin with healthy pregnancies including risk factor assessment and screening of mothers. Such routine maternal screening and treatment does or may include glucose tolerance tests, ultrasound examinations, screenings for maternal blood type (with appropriate administration of Rho(D) immunoglobulin if appropriate), Hepatitis B, Neisseria gonorrhea, Chlamydia, Cyt...
Source: PediatricEducation.org - November 20, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
How Late Can You Give Routine Newborn Care?
Discussion
Routine newborn screening and treatment is focused on assisting the infant’s transition to extrauterine life, screening for health problems that may or may not be easily identifiable, and preventing acute or chronic health problems. Healthy infants begin with healthy pregnancies including risk factor assessment and screening of mothers. Such routine maternal screening and treatment does or may include glucose tolerance tests, ultrasound examinations, screenings for maternal blood type (with appropriate administration of Rho(D) immunoglobulin if appropriate), Hepatitis B, Neisseria gonorrhea, Chlamydia, Cyt...
Source: PediatricEducation.org - November 20, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Acute Liver Failure Due to Herpes Simplex Viral Hepatitis Acute Liver Failure Due to Herpes Simplex Viral Hepatitis
While a rare occurrence, this case underscores the need to be aware of HSV hepatitis as a possible cause of acute liver failure.Journal of Medical Case Reports (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - October 27, 2023 Category: Pathology Tags: Family Medicine/Primary Care Journal Article Source Type: news
Experimental therapy fights untreatable brain cancer with genetically modified HERPES virus
Researchers from Boston, Massachusetts found the herpes simplex virus can trigger a response in the body that would provoke a person's immune system to attack brain cancer cells. (Source: the Mail online | Health)
Source: the Mail online | Health - October 19, 2023 Category: Consumer Health News Source Type: news
Intimate partner violence is associated with cytomegalovirus among young women in rural South Africa: an HPTN 068 analysis - Kelly NK, G ómez-Olivé FX, Wagner LD, Aiello AE, Kahn K, Pettifor A, Stoner MCD.
ABSTRACTStressful life circumstances (e.g. violence and poverty) have been associated with elevated biomarkers, including C-reactive protein (CRP), cytomegalovirus (CMV), and herpes simplex virus type-1 (HSV-1), among older adults in high-income settings. ... (Source: SafetyLit)
Source: SafetyLit - September 19, 2023 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
TREMFYA ® (guselkumab) Provides Sustained Improvements Across All Minimal Disease Activity Domains for Adults Living with Active Psoriatic Arthritis in Phase 3b Trial
SPRING HOUSE, PENNSYLVANIA, May 31, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 3b COSMOS clinical trial showing that treatment with TREMFYA® (guselkumab) provided sustainable improvements in all minimal disease activity (MDA)a domains through week 48 in adults living with active psoriatic arthritis (PsA) who previously had an inadequate response to one to two tumor necrosis factor inhibitors (TNFi-IR).[1] In a separate post-hoc analysis of the Phase 3 DISCOVER-1 and DISCOVER-2b clinical trial findings, TREMFYA was shown to be associated with prompt and su...
Source: Johnson and Johnson - May 31, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Video: 3 things you didn't know about cold sores
(Source: MayoClinic.com Full Feed)
Source: MayoClinic.com Full Feed - May 20, 2023 Category: Consumer Health News Source Type: news
First Phase 3 TREMFYA ® (guselkumab) Data in Inflammatory Bowel Disease Show Positive Induction Results Among Patients with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, May 9, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new efficacy and safety data from the Phase 3 QUASAR Induction Study evaluating the investigational use of TREMFYA® (guselkumab) in adults with moderately to severely active ulcerative colitis (UC)a who had an inadequate response or intolerance to conventionalb and/or advanced therapies.1,c The data show statistically significant and clinically meaningful improvements across symptomatic and histo-endoscopic outcome measures.1 Safety data were also consistent with the known safety profile of TREMFYA in ...
Source: Johnson and Johnson - May 9, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
TREMFYA ® (guselkumab) Real-World Data Analyses Show Greater Treatment Persistence Than IL-17s in Both Bio-naïve and Bio-experienced Patients Living With Moderate to Severe Plaque Psoriasis
SPRING HOUSE, PENNSYLVANIA, March 17, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data, showing that initiation of TREMFYA® (guselkumab) was associated with greater treatment persistencea compared to secukinumab or ixekizumab in bio-naïve and bio-experienced patientsb living with moderate to severe plaque psoriasis (PsO), based on pairwise analysesc of real-world data.[1],[2] Additionally, in a post-hoc analysis of Phase 3 VOYAGE 2 clinical trial results, TREMFYA demonstrated durable clinical efficacy, itch relief and quality-of-life improvements in patients living with scal...
Source: Johnson and Johnson - March 17, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
TREMFYA ® (guselkumab) Demonstrates a Differentiated Binding Mechanism from Risankizumab in In Vitro Studies
SPRING HOUSE, PENNSYLVANIA, March 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced additional results from in vitro MODIF-Y studies, which continue to support a hypothesis that not all IL-23 inhibitors are the same by demonstrating a differentiated binding mechanism for TREMFYA® (guselkumab) from risankizumab. Findings show that guselkumab is able to dose-dependently bind to CD64+a myeloid cells,1 the predominant source of IL-23-driven inflammation in the gut.2,b Data comprise one of Janssen’s 22 oral and poster presentations at the 18th Congress of the European Crohn’s and Col...
Source: Johnson and Johnson - March 3, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
